About Us

Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology is rediscovering Bisantrene. We own recent patent filings on Bisantrene and have secured Orphan Drug Designation in the US. Now our goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. 

In The News

ASX Announcements

6th December

Details of Company Address


22nd November

Appendix 3Y-Brendan de Kauwe


22nd November

Appendix 3Y-Chris Ntoumenopoulos


News Articles

4th September

Boss behind Betadine in race for new cancer drug

Read More

31st August

Race Oncology on ABC TV News

Read More

31st August

Peter Molloy eyes discarded cancer drugs

Read More

30th August

Race challenges big pharma mindset

Read More

14th August

New cancer hope with drug Big Pharma overlooked

Read More


22nd September

Independent Investment Research

Read More

What is Bisantrene?

Bisantrene is a cancer drug that is related to the anthracyclines, the most widely used class of chemotherapy drugs.

Bisantrene is a cancer chemotherapy drug related to the anthracyclines, a class of drugs used as the first line of treatment for AML and many other cancers. However, one of the disadvantages of anthracyclines is their risk of cardiac toxicity and consequent heart failure. This means that once patients have received an amount of anthracyclines that approaches the maximum recommended dose to avoid cardio-toxicity, the oncologist may have to stop treatment, even when the drug is working. In addition, anthracyclines are associated with high levels of cancer drug resistance after initial treatment. Essentially, this means that the after an initial remission, the cancer relapses and progresses.

An article titled: “The Rediscovery of Bisantrene: A Review of the Literature” was recently published in the International Journal of Cancer Research & Therapy. The author of the article is Dr John Rothman, Chief Scientific Officer of Race Oncology. The article can be viewed online here.

Bisantrene has been shown to have greatly reduced cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines. This makes Bisantrene potentially well-suited as a second- or third-line treatment for patients who have reached their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. 


Bisantrene was discovered by the US pharmaceutical company Lederle (a division of American Cyanamid) in the 1970s. Through the 1980s and into the early 1990's, Bisantrene was tested in more than 40 published phase II clinical trials, including 33 clinical trials at the National Cancer Institute (NCI) in the US, to assess its efficacy and safety in a wide range of cancers. In these studies, in total covering more than 2,000 treated patients, Bisantrene was shown to possess low cardiotoxicity potential and useful therapeutic efficacy in several cancers, notably AML (Acute Myeloid Leukaemia).

Acute myeloid leukaemia (AML)

Despite all the improvements in treatment for breast and other cancers, the treatment of AML has not changed appreciably in the last three decades. Today, it remains a disease of the elderly with a high unmet medical need, especially once anthracycline and other chemotherapy treatments fail.

Mode of Action

In addition to its direct cytotoxic actions (like other chemotherapy drugs), Bisantrene has also been shown to have immunologic and genomic effects. In allogeneic transplant (animal) models, Bisantrene has been found to activate macrophages (one type of immune cell) to attack and destroy tumour cells. Further, it binds to DNA at a site that displaces telomerase binding proteins, enabling tumour cells to regain their mortality and die of old age (apoptosis), rather than continue to proliferate.

Because of these additional immune-stimulating and apoptotic mechanisms of action, Race Oncology believes that Bisantrene may have an important role in certain cancers in combination with some of the new immunotherapeutic agents.

Race Oncology plans to generate early sales revenues under a Named Patient Program.

Development Plan

Race Oncology intends to file an IND (Investigational New Drug application) to enable completion of the clinical development and ultimately approval of Bisantrene in the US for the treatment of AML.

Board & Management

Peter Molloy

Chief Executive Officer

Peter Molloy graduated from the University of Melbourne as a microbiologist and biochemist and then worked for 18 years in the pharmaceutical industry. At the Australian pharmaceutical company, Faulding, he managed several Faulding subsidiaries, before joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations, where he managed four pharmaceutical marketing divisions including the oncology business. Promoted to Vice President of Strategic Marketing, he was then responsible for Pharmacia’s marketing strategy and portfolio across 22 countries throughout Asia-Pacific and Latin America.

Dr John Rothman

Chief Scientific Officer

Dr John Rothman was a clinical scientist at the pharmaceutical companies, Schering Plough and Roche, where he was also a Clinical Director for a number of different therapeutic areas and Senior Director for all of Roche’s data acquisition, statistical analysis and report writing for all experimental and approved drugs in the Roche portfolio. His work on interferon-α in AIDS-related Kaposi’s Sarcoma (a type of cancer) resulted in the approval of first recombinant drug and AIDS treatment in the 1980s, called Roferon-A. Subsequently as an R&D Director at Roche, Dr Rothman was associated with a number of development programs that resulted in marketed drugs, including Rocephin, Coactin, Midazolam, Rimadyl, Larotid, Dalmane, Rimantidine, Versed and others, as well as providing post-marketing support for numerous drugs.

Gordon Beck

Senior Vice President Business Development

Mr Beck has an impressive commercial background in the pharmaceutical industry. He worked for 13 years in senior roles at Roche and Bristol-Myers Squibb. At Roche, he was Global Business Team leader for oncology, infectious diseases, cardiovascular disease, and CNS drugs. Subsequently, at BMS, he was Director, Cardiovascular Marketing and Business Development, providing leadership for the commercialization of the blockbuster cardiovascular drug, Plavix®. Subsequently, he consulted in strategic planning, medical communications and business development with leading companies including Amgen, Genentech, Novartis, Seattle Genetics, BMS, Gilead and Takeda.

Dr William Garner


William Garner MD, is a US physician and entrepreneur. Dr Garner is one of the inventors on the Bisantrene patents, originally filed by Update Pharma, Inc. and now owned by Race Oncology. Previously, he founded EGB Advisors LLC, a life sciences advisory firm whose clients have included the M.D. Anderson Cancer Center, the Kauffman Foundation, ChemGenex (ASX:CXS) and CoTherix. He also founded Inverseon, Inc., which was merged with the ASX-listed company cBio to create Invion Ltd, serving as CEO until May of 2013. He also founded Urigen Pharmaceuticals, Inc. and co-founded DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI). Previously, he was at Hoffmann La Roche in oncology medical affairs and worked as a merchant banker in New York City.

Dr Brendan de Kauwe


Dr de Kauwe completed a Bachelor of Science and Bachelor of Dental Surgery at the University of Western Australia. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance, and is an ASIC compliant (RG146) Securities Advisor. Dr de Kauwe is a Director of Otsana Capital, a corporate advisory firm, and has extensive experience in corporate restructuring and recapitalisations, mergers and acquisitions, IPO/RTO and capital markets. Dr de Kauwe’s corporate experience, coupled with his extensive technology, science and bio-medical background gives him an integral understanding in the evaluation and execution of projects and assets over a diverse range of sectors.

Chris Ntoumenopoulos


Mr Chris Ntoumenopoulos is Managing Director at Twenty 1 Corporate, a boutique corporate advisory firm. He has worked in financial markets for the past 12 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO. He is also a director of various private and public companies which span across finance, technology and medical sectors.

Contact Us

Registered Office
Race Oncology Ltd
L2, 710 Collins St
Docklands VIC 3008
+61 3 9097 1656
Automic Registry Services
Level 2, 267 St Georges Terrace
Perth WA 6000
1300 288 664 (within Australia)
All the fields are required